Approval of the high-cost new drug for leukemia, "Kymriah."
グラフトン
The Ministry of Health, Labour and Welfare's expert committee seems to have approved the manufacturing and sale of "Kymriah," which Novartis Pharma applied for as a treatment for acute lymphoblastic leukemia using regenerative medicine.
Due to the high cost of medical care, there is likely to be increased interest in the out-of-pocket expenses in Japan.
Our "Children's Air Coat" helps reduce formaldehyde present in the air we breathe every day and assists in addressing the risk of leukemia!
Inquiry about this news
Contact Us OnlineMore Details & Registration
Details & Registration
Related Links
Approval of expensive new drug for leukemia